368 related articles for article (PubMed ID: 19520778)
21. piR-31470 epigenetically suppresses the expression of glutathione S-transferase pi 1 in prostate cancer via DNA methylation.
Zhang L; Meng X; Pan C; Qu F; Gan W; Xiang Z; Han X; Li D
Cell Signal; 2020 Mar; 67():109501. PubMed ID: 31837464
[TBL] [Abstract][Full Text] [Related]
22. [TMPRSS2-ETS gene fusion in prostate cancer].
Perner S; Schmidt FH; Hofer MD; Kuefer R; Rubin M
Urologe A; 2007 Jul; 46(7):754-60. PubMed ID: 17458530
[TBL] [Abstract][Full Text] [Related]
23. Glutathione S-transferase pi (GSTP1) hypermethylation in prostate cancer: review 2007.
Meiers I; Shanks JH; Bostwick DG
Pathology; 2007 Jun; 39(3):299-304. PubMed ID: 17558856
[TBL] [Abstract][Full Text] [Related]
24. A reciprocal role of prostate cancer on stromal DNA damage.
Banerjee J; Mishra R; Li X; Jackson RS; Sharma A; Bhowmick NA
Oncogene; 2014 Oct; 33(41):4924-31. PubMed ID: 24141771
[TBL] [Abstract][Full Text] [Related]
25. Fusion in the ETS gene family and prostate cancer.
Narod SA; Seth A; Nam R
Br J Cancer; 2008 Sep; 99(6):847-51. PubMed ID: 18781147
[TBL] [Abstract][Full Text] [Related]
26. TMPRSS2 fusions with oncogenic ETS factors in prostate cancer involve unbalanced genomic rearrangements and are associated with HDAC1 and epigenetic reprogramming.
Iljin K; Wolf M; Edgren H; Gupta S; Kilpinen S; Skotheim RI; Peltola M; Smit F; Verhaegh G; Schalken J; Nees M; Kallioniemi O
Cancer Res; 2006 Nov; 66(21):10242-6. PubMed ID: 17079440
[TBL] [Abstract][Full Text] [Related]
27. Epigenetic regulation of prostate cancer: the theories and the clinical implications.
Liao Y; Xu K
Asian J Androl; 2019; 21(3):279-290. PubMed ID: 30084432
[TBL] [Abstract][Full Text] [Related]
28. Micro-RNA-204 Participates in TMPRSS2/ERG Regulation and Androgen Receptor Reprogramming in Prostate Cancer.
Todorova K; Metodiev MV; Metodieva G; Mincheff M; Fernández N; Hayrabedyan S
Horm Cancer; 2017 Feb; 8(1):28-48. PubMed ID: 28050800
[TBL] [Abstract][Full Text] [Related]
29. Epigenetic modifications in prostate cancer.
Sugiura M; Sato H; Kanesaka M; Imamura Y; Sakamoto S; Ichikawa T; Kaneda A
Int J Urol; 2021 Feb; 28(2):140-149. PubMed ID: 33111429
[TBL] [Abstract][Full Text] [Related]
30. Recent Advances in Epigenetic Biomarkers and Epigenetic Targeting in Prostate Cancer.
Kumaraswamy A; Welker Leng KR; Westbrook TC; Yates JA; Zhao SG; Evans CP; Feng FY; Morgan TM; Alumkal JJ
Eur Urol; 2021 Jul; 80(1):71-81. PubMed ID: 33785255
[TBL] [Abstract][Full Text] [Related]
31. The molecular pathogenesis of prostate cancer: Implications for prostate cancer prevention.
Nelson WG; De Marzo AM; DeWeese TL
Urology; 2001 Apr; 57(4 Suppl 1):39-45. PubMed ID: 11295593
[TBL] [Abstract][Full Text] [Related]
32. Expression level and DNA methylation status of glutathione-S-transferase genes in normal murine prostate and TRAMP tumors.
Mavis CK; Morey Kinney SR; Foster BA; Karpf AR
Prostate; 2009 Sep; 69(12):1312-24. PubMed ID: 19444856
[TBL] [Abstract][Full Text] [Related]
33. ETS family-associated gene fusions in Japanese prostate cancer: analysis of 194 radical prostatectomy samples.
Miyagi Y; Sasaki T; Fujinami K; Sano J; Senga Y; Miura T; Kameda Y; Sakuma Y; Nakamura Y; Harada M; Tsuchiya E
Mod Pathol; 2010 Nov; 23(11):1492-8. PubMed ID: 20693979
[TBL] [Abstract][Full Text] [Related]
34. A tissue biopsy-based epigenetic multiplex PCR assay for prostate cancer detection.
Van Neste L; Bigley J; Toll A; Otto G; Clark J; Delrée P; Van Criekinge W; Epstein JI
BMC Urol; 2012 Jun; 12():16. PubMed ID: 22672250
[TBL] [Abstract][Full Text] [Related]
35. Using Genetic and Epigenetic Markers to Improve Differential Diagnosis of Prostate Cancer and Benign Prostatic Hyperplasia by Noninvasive Methods in Mexican Patients.
Sánchez BE; Aguayo A; Martínez B; Rodríguez F; Marmolejo M; Svyryd Y; Luna L; Muñoz LA; Jiménez MA; Sotomayor M; Vargas V F; Mutchinick OM
Clin Genitourin Cancer; 2018 Aug; 16(4):e867-e877. PubMed ID: 29571584
[TBL] [Abstract][Full Text] [Related]
36. Predicting prostate biopsy result in men with prostate specific antigen 2.0 to 10.0 ng/ml using an investigational prostate cancer methylation assay.
Baden J; Adams S; Astacio T; Jones J; Markiewicz J; Painter J; Trust C; Wang Y; Green G
J Urol; 2011 Nov; 186(5):2101-6. PubMed ID: 21944123
[TBL] [Abstract][Full Text] [Related]
37. The epigenetic promise for prostate cancer diagnosis.
Van Neste L; Herman JG; Otto G; Bigley JW; Epstein JI; Van Criekinge W
Prostate; 2012 Aug; 72(11):1248-61. PubMed ID: 22161815
[TBL] [Abstract][Full Text] [Related]
38. DNA hypomethylation arises later in prostate cancer progression than CpG island hypermethylation and contributes to metastatic tumor heterogeneity.
Yegnasubramanian S; Haffner MC; Zhang Y; Gurel B; Cornish TC; Wu Z; Irizarry RA; Morgan J; Hicks J; DeWeese TL; Isaacs WB; Bova GS; De Marzo AM; Nelson WG
Cancer Res; 2008 Nov; 68(21):8954-67. PubMed ID: 18974140
[TBL] [Abstract][Full Text] [Related]
39. Epigenetic modifications of prostate-derived Ets transcription factor in breast cancer cells.
Sabherwal Y; Mahajan N; Zhang M
Oncol Rep; 2013 Oct; 30(4):1985-8. PubMed ID: 23921628
[TBL] [Abstract][Full Text] [Related]
40. Epigenetic modifications in prostate cancer.
Ngollo M; Dagdemir A; Karsli-Ceppioglu S; Judes G; Pajon A; Penault-Llorca F; Boiteux JP; Bignon YJ; Guy L; Bernard-Gallon DJ
Epigenomics; 2014; 6(4):415-26. PubMed ID: 25333850
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
